METHODS: A retrospective analysis was conducted on patients who underwent endovascular treatment for symptomatic subclavian artery stenosis or occlusion between October 2013 and April 2022. Clinical characteristics, procedural details, short- and long-term outcomes, and patency rates were assessed.
RESULTS: Twenty-five patients were included in the study, with a mean age of 56.8 years. The majority of patients had risk factors for atherosclerosis, and all presented with symptoms related to subclavian artery disease. The endovascular procedures were successful in 96% of cases, with a low complication rate of 8%. During a median follow-up of 43 months, the overall patency rate was 92% at three years.
CONCLUSIONS: Endovascular treatment of subclavian artery stenosis and occlusion is a safe and effective option, with excellent long-term patency rates. These findings support the use of percutaneous revascularization as the first-line therapy, particularly in experienced centers. Further studies with larger sample sizes and longer follow-up periods are needed to confirm these results.
方法:对2013年10月至2022年4月期间因症状性锁骨下动脉狭窄或闭塞而接受腔内治疗的患者进行回顾性分析。临床特征,程序细节,短期和长期结果,和通畅率进行了评估。
结果:25名患者被纳入研究,平均年龄56.8岁.大多数患者有动脉粥样硬化的危险因素,所有患者均出现与锁骨下动脉疾病相关的症状。96%的病例血管内手术成功,并发症发生率低,为8%。在43个月的中位随访中,三年的总通畅率为92%。
结论:血管内治疗锁骨下动脉狭窄和闭塞是一种安全有效的选择,具有出色的长期通畅率。这些发现支持使用经皮血运重建作为一线治疗,特别是在有经验的中心。需要更大样本量和更长随访期的进一步研究来证实这些结果。